MOD3 Pharma combines decades of CMC experience with a laser focus on Orally Inhaled and Nasal Drug Products (OINDP) to transform your investigational drug into a clinic ready product. Using a stage appropriate methodology within the Module 3 framework, our experts work with you to manage risk, mitigate delay and reduce cost while ensuring your OINDP product's quality, safety, and efficacy. Risk. Time. Cost. The trifecta of challenges that can keep you awake at night. Because your project matters – it really matters, not just to you, but to the patients that will rely on your therapy to make their lives better. Specifically supporting clients working within phases 1&2 of clinical trials, MOD3 Pharma’s capabilities include spray drying, semi-automated filling and assembly for single dose powder and liquid nasal systems, bi-dose and multidose nasal devices. This service proposition uniquely fills the gap for organizations needing early phase clinical supplies.
| Website | http://www.mod3pharma.com |
| Employees | 13 (7 on RocketReach) |
| Founded | 2013 |
| Address | 83 Fulton St., Boonton, New Jersey 07005, US |
| Industry | Pharmaceutical Manufacturing |
Looking for a particular MOD3 Pharma employee's phone or email?
Tom Daggs is the Vice President, Product Development and Quality Control of MOD3 Pharma.
7 people are employed at MOD3 Pharma.
MOD3 Pharma is based in Boonton, New Jersey.